Whitnell & Co’s NxStage Medical Inc. NXTM Stock Holding History

Whitnell & Co’s Portfolio NXTM Stock Details NXTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-500	Closed	-$13K	–	385
2016 Q4	$13K	Hold	500	–	–	0.01%	234
2016 Q3	$12K	Buy	+500	New	+$11.7K	﹤0.01%	234

Other funds holding NXTM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

PCM

Pennant Capital Management Summit, New Jersey $212M AUM 19.37% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Whitnell & Co's NXTM Position: Q1 2017 in Review

Whitnell & Co sold out of NxStage Medical Inc. (NXTM) in Q1 2017, closing a stake of 500 shares — an estimated $13K sold.

Whitnell & Co first reported a position in NXTM in Q3 2016 and held it in 2 quarters. The position peaked at $13K in Q4 2016. 171 funds tracked by Wall St. Rank hold NXTM as of Q1 2017.

Whitnell & Co reported no remaining NxStage Medical Inc. position as of Q1 2017 after selling out during the quarter.
Whitnell & Co sold 500 NxStage Medical Inc. shares in Q1 2017, an estimated $13K.
Whitnell & Co first reported a position in NxStage Medical Inc. in Q3 2016 and held it in 2 quarters.
Whitnell & Co's NxStage Medical Inc. position peaked at $13K in Q4 2016.
171 funds tracked by Wall St. Rank held NxStage Medical Inc. as of Q1 2017.

Based on Whitnell & Co's 13F filing for Q1 2017, filed 19 Apr 2017.